Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for brensocatib, intended for patients with non-cystic fibrosis bronchiectasis. The FDA has granted priority review for the application and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act.